Artificial intelligence in urological malignancy diagnosis and prognosis: current status and future prospects - PubMed
3 days ago
- #Diagnosis
- #Urological Cancers
- #Artificial Intelligence
- AI is transforming the diagnosis of urological malignancies like prostate cancer, bladder cancer, and renal cell carcinoma (RCC).
- AI integrates imaging, pathology, and molecular data to improve tumor detection, grading, and risk stratification.
- In prostate cancer, AI enhances MRI and digital pathology for lesion localization and Gleason scoring.
- For bladder cancer, deep learning aids in cystoscopy and CT/MRI-based biomarker prediction (e.g., PD-L1 expression).
- In RCC, AI combined with CT/MRI and multi-omics data supports subtype classification and personalized therapy.
- Challenges include data standardization, model generalizability, interpretability, and regulatory compliance.
- The review highlights AI's innovations, clinical challenges, and future opportunities in urological cancer care.